HRP20120828T1 - Cjepivo - Google Patents
Cjepivo Download PDFInfo
- Publication number
- HRP20120828T1 HRP20120828T1 HRP20120828AT HRP20120828T HRP20120828T1 HR P20120828 T1 HRP20120828 T1 HR P20120828T1 HR P20120828A T HRP20120828A T HR P20120828AT HR P20120828 T HRP20120828 T HR P20120828T HR P20120828 T1 HRP20120828 T1 HR P20120828T1
- Authority
- HR
- Croatia
- Prior art keywords
- protein
- cancer
- fusion protein
- fusion
- vaccine
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims 6
- 108020001507 fusion proteins Proteins 0.000 claims 11
- 102000037865 fusion proteins Human genes 0.000 claims 11
- 238000000034 method Methods 0.000 claims 5
- 150000007523 nucleic acids Chemical group 0.000 claims 5
- 230000012743 protein tagging Effects 0.000 claims 5
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims 3
- 102000036673 PRAME Human genes 0.000 claims 3
- 108060006580 PRAME Proteins 0.000 claims 3
- 101710188053 Protein D Proteins 0.000 claims 3
- 101710132893 Resolvase Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 241000894006 Bacteria Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000007801 affinity label Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- -1 Met-Asp-Pro amino acids Chemical class 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000006037 cell lysis Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (18)
1. Fuzijski protein, naznačen time što se sastoji od:
(a) antigena raka testisa PRAME;
(b) heterolognog proteinskog partnera u fuziji, izvedenog iz proteina D, gdje proteinski partner u fuziji sadrži aminokiseline 20 do 127 proteina D; i
(c) dodatne aminokiseline Met-Asp-Pro na N-terminalnom kraju slijeda fuzijskog proteina
gdje je heterologni proteinski partner u fuziji izveden iz proteina D, (b), fuzioniran s N-krajem PRAME.
2. Fuzijski protein u skladu s patentnim zahtjevom 1, naznačen time što dodatno sadrži afinitetni biljeg.
3. Fuzijski protein u skladu s patentnim zahtjevom 2, naznačen time što je afinitetni biljeg histidinski rep.
4. Fuzijski protein u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što dodatno sadrži jedan ili više sljedova spojnica između proteinskog partnera u fuziji i PRAME; ili između proteinskog partnera u fuziji i afinitetnog biljega; ili između PRAME i afinitetnog biljega.
5. Nukleinskokiselinski slijed, naznačen time što kodira fuzijski protein u skladu s bilo kojim od patentnih zahtjeva 1 do 4.
6. Vektor, naznačen time što sadrži nukleinskokiselinski slijed u skladu s patentnim zahtjevom 5.
7. Izolirana stanica-domaćin, naznačena time što je transformirana vektorom u skladu s patentnim zahtjevom 6.
8. Cjepivo, naznačeno time što sadrži fuzijski protein u skladu s bilo kojim od patentnih zahtjeva 1 do 4, ili nukleinsku kiselinu u skladu s patentnim zahtjevom 5, ili vektor u skladu s patentnim zahtjevom 6.
9. Cjepivo u skladu s patentnim zahtjevom 8, naznačeno time što dodatno sadrži adjuvans, i/ili imunostimulacijski citokin ili kemokin.
10. Cjepivo u skladu s patentnim zahtjevom 9, naznačeno time što adjuvans sadrži oligonukleotid 3D-MPL, QS21 i/ili CpG.
11. Cjepivo u skladu s bilo kojim od patentnih zahtjeva 8 do 10, naznačeno time što je namijenjeno upotrebi u medicini.
12. Upotreba proteina ili nukleinske kiseline ili vektora u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačena time što su protein ili nukleinska kiselina ili vektor namijenjeni proizvodnji cjepiva za imunoterapijsko liječenje pacijenta koji boluje od raka.
13. Postupak dobivanja fuzijskog proteina, naznačen time što se sastoji u koraku eksprimiranja u izoliranoj stanici fuzijskog proteina u skladu s bilo kojim od patentnih zahtjeva 1 do 4.
14. Postupak u skladu s patentnim zahtjevom 13, naznačen time što je stanica bakterija.
15. Postupak u skladu s patentnim zahtjevom 14, naznačen time što je bakterija E. coli.
16. Postupak u skladu s patentnim zahtjevom 16, naznačen time što je dodatno uključen korak lize stanice i pročišćavanja eksprimiranog fuzijskog proteina iz liziranih stanica
17. Fuzijski protein, naznačen time što se dobiva ili se može dobiti postupkom u skladu s bilo kojim od patentnih zahtjeva 13 do 16.
18. Upotreba u skladu s patentnim zahtjevom 12, naznačena time što se rak bira između melanoma, raka dojke, mokraćnog mjehura, pluća, primjerice NSCLC, sarkoma, raka jajnika, raka glave i vrata, raka bubrega, kolorektalnog karcinoma, multiplog mijeloma, leukemije, uključujući akutnu leukemiju i karcinoma jednjaka.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0700760A GB0700760D0 (en) | 2007-01-15 | 2007-01-15 | Vaccine |
| GB0701262A GB0701262D0 (en) | 2007-01-23 | 2007-01-23 | Vaccine |
| PCT/EP2008/050290 WO2008087102A1 (en) | 2007-01-15 | 2008-01-11 | Vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120828T1 true HRP20120828T1 (hr) | 2012-11-30 |
Family
ID=39300029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120828AT HRP20120828T1 (hr) | 2007-01-15 | 2012-10-15 | Cjepivo |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20080187535A1 (hr) |
| EP (1) | EP2114993B1 (hr) |
| JP (1) | JP5391080B2 (hr) |
| KR (1) | KR20090101313A (hr) |
| CN (1) | CN101668770B (hr) |
| AR (1) | AR064862A1 (hr) |
| AU (1) | AU2008207025B2 (hr) |
| BR (1) | BRPI0806463A2 (hr) |
| CA (1) | CA2674552A1 (hr) |
| CL (1) | CL2008000104A1 (hr) |
| CO (1) | CO6210757A2 (hr) |
| CR (1) | CR10971A (hr) |
| CY (1) | CY1113760T1 (hr) |
| DK (1) | DK2114993T3 (hr) |
| DO (1) | DOP2009000167A (hr) |
| EA (1) | EA016326B1 (hr) |
| ES (1) | ES2393812T3 (hr) |
| HK (1) | HK1138853A1 (hr) |
| HR (1) | HRP20120828T1 (hr) |
| IL (1) | IL199663A0 (hr) |
| JO (1) | JO2840B1 (hr) |
| MA (1) | MA31093B1 (hr) |
| MX (1) | MX2009007571A (hr) |
| MY (1) | MY153679A (hr) |
| NZ (1) | NZ578285A (hr) |
| PE (2) | PE20130324A1 (hr) |
| PL (1) | PL2114993T3 (hr) |
| PT (1) | PT2114993E (hr) |
| SI (1) | SI2114993T1 (hr) |
| TW (1) | TWI434697B (hr) |
| WO (1) | WO2008087102A1 (hr) |
| ZA (1) | ZA200904923B (hr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0806501A2 (pt) * | 2007-01-15 | 2014-04-22 | Glaxosmithkline Biolog Sa | Proteína de fusão, molécula de ácido nucleico, vetor, célula hospedeira, vacina ou composição imunogênica, e, uso da proteína de fusão. |
| MX2011009597A (es) | 2009-03-17 | 2012-05-29 | Glaxosmithkline Biolog Sa | Deteccion mejorada de la expresion del gen. |
| JP2012529269A (ja) * | 2009-06-05 | 2012-11-22 | ジ オハイオ ステイト ユニヴァーシティ リサーチ ファウンデーション | 生体材料、組成物及び方法 |
| GB0910046D0 (en) | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
| GB201008682D0 (en) * | 2010-05-25 | 2010-07-07 | Vib Vzw | Epitope tag for affinity based applications |
| GB201101331D0 (en) * | 2011-01-26 | 2011-03-09 | Glaxosmithkline Biolog Sa | Compositions and uses |
| JP2014529338A (ja) * | 2011-07-22 | 2014-11-06 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Ｐｒａｍｅの精製 |
| GB201114919D0 (en) * | 2011-08-30 | 2011-10-12 | Glaxosmithkline Biolog Sa | Method |
| GB201116248D0 (en) | 2011-09-20 | 2011-11-02 | Glaxosmithkline Biolog Sa | Liposome production using isopropanol |
| RU2590701C2 (ru) * | 2013-04-29 | 2016-07-10 | Общество с ограниченной ответственностью "ГеноТехнология" | Антигенная композиция и ее терапевтическое применение для профилактики и лечения онкологических заболеваний, рекомбинантная плазмидная днк, обеспечивающая синтез гибридного белка, а также способ получения белка |
| EP3053592A4 (en) | 2013-10-01 | 2017-09-06 | Mie University | T cell-inducing vaccine containing interepitope sequence promoting antigen presentation |
| CN105254767A (zh) * | 2015-11-17 | 2016-01-20 | 重庆科润生物医药研发有限公司 | 一种Protein D与HER2融合蛋白及其制备方法和应用 |
| SG10202105561PA (en) | 2016-11-30 | 2021-07-29 | Advaxis Inc | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof |
| CN108264550B (zh) * | 2017-01-04 | 2021-04-23 | 香雪生命科学技术（广东）有限公司 | 一种识别源自于prame抗原短肽的tcr |
| CN108948184B (zh) * | 2017-05-22 | 2021-04-23 | 香雪生命科学技术（广东）有限公司 | 一种识别衍生自prame抗原短肽的t细胞受体 |
| CN109400697B (zh) * | 2017-08-17 | 2021-04-23 | 香雪生命科学技术（广东）有限公司 | 一种识别prame抗原短肽的tcr及其相关组合物 |
| WO2019061297A1 (zh) * | 2017-09-29 | 2019-04-04 | 苏州工业园区唯可达生物科技有限公司 | 一种cd4辅助性t细胞表位融合肽及其疫苗 |
| US20210177955A1 (en) * | 2017-11-08 | 2021-06-17 | Advaxis, Inc. | Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof |
| CN109879957B (zh) * | 2017-12-06 | 2022-03-18 | 香雪生命科学技术（广东）有限公司 | 针对prame的高亲和力t细胞受体 |
| US20230190902A1 (en) * | 2020-05-29 | 2023-06-22 | Children's National Medical Center | Identification of hla-restricted prame peptide epitopes, prame-specific t cells suitable for "off-the-shelf" treatment of cancer expressing prame |
| JP2024518378A (ja) | 2021-05-05 | 2024-05-01 | イマティクス バイオテクノロジーズ ゲーエムベーハー | Ｐｒａｍｅに特異的に結合する抗原結合タンパク質 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE466259B (sv) * | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| CA2156718A1 (en) * | 1993-12-23 | 1995-06-29 | Bruno Gander | Immunological response potentiation process |
| US5830753A (en) * | 1994-09-30 | 1998-11-03 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof. |
| GB9717953D0 (en) * | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
| SI1659178T1 (sl) * | 1998-02-05 | 2010-07-30 | Glaxosmithkline Biolog Sa | Postopek za čiščenje ali proizvodnjo MAGE proteina |
| EP1156825A2 (en) * | 1999-02-25 | 2001-11-28 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Immunogens comprising a peptide and a carrier derived from h.influenzae protein d |
| DE60023300T2 (de) * | 1999-06-29 | 2006-07-06 | Glaxosmithkline Biologicals S.A. | Verwendung von cpg als adjuvans für hivimpstoff |
| EP1196772A2 (en) * | 1999-07-08 | 2002-04-17 | Stressgen Biotechnologies Corporation | Induction of a th1-like response in vitro |
-
2008
- 2008-01-11 CA CA002674552A patent/CA2674552A1/en not_active Abandoned
- 2008-01-11 SI SI200830787T patent/SI2114993T1/sl unknown
- 2008-01-11 TW TW097101177A patent/TWI434697B/zh not_active IP Right Cessation
- 2008-01-11 PE PE2012001372A patent/PE20130324A1/es not_active Application Discontinuation
- 2008-01-11 PL PL08701434T patent/PL2114993T3/pl unknown
- 2008-01-11 PT PT08701434T patent/PT2114993E/pt unknown
- 2008-01-11 EA EA200900795A patent/EA016326B1/ru not_active IP Right Cessation
- 2008-01-11 KR KR1020097017027A patent/KR20090101313A/ko not_active Application Discontinuation
- 2008-01-11 DK DK08701434.6T patent/DK2114993T3/da active
- 2008-01-11 JP JP2009545186A patent/JP5391080B2/ja not_active Expired - Fee Related
- 2008-01-11 AR ARP080100127A patent/AR064862A1/es active IP Right Grant
- 2008-01-11 WO PCT/EP2008/050290 patent/WO2008087102A1/en active Application Filing
- 2008-01-11 CN CN2008800078884A patent/CN101668770B/zh not_active Expired - Fee Related
- 2008-01-11 BR BRPI0806463-6A patent/BRPI0806463A2/pt not_active IP Right Cessation
- 2008-01-11 AU AU2008207025A patent/AU2008207025B2/en not_active Ceased
- 2008-01-11 MY MYPI20092932A patent/MY153679A/en unknown
- 2008-01-11 ES ES08701434T patent/ES2393812T3/es active Active
- 2008-01-11 MX MX2009007571A patent/MX2009007571A/es active IP Right Grant
- 2008-01-11 US US12/013,011 patent/US20080187535A1/en not_active Abandoned
- 2008-01-11 PE PE2008000124A patent/PE20081686A1/es not_active Application Discontinuation
- 2008-01-11 EP EP08701434A patent/EP2114993B1/en not_active Not-in-force
- 2008-01-11 NZ NZ578285A patent/NZ578285A/en not_active IP Right Cessation
- 2008-01-13 JO JO200815A patent/JO2840B1/en active
- 2008-01-14 CL CL200800104A patent/CL2008000104A1/es unknown
-
2009
- 2009-07-02 DO DO2009000167A patent/DOP2009000167A/es unknown
- 2009-07-02 IL IL199663A patent/IL199663A0/en unknown
- 2009-07-10 MA MA32087A patent/MA31093B1/fr unknown
- 2009-07-14 ZA ZA2009/04923A patent/ZA200904923B/en unknown
- 2009-07-15 CO CO09073705A patent/CO6210757A2/es not_active Application Discontinuation
- 2009-08-07 CR CR10971A patent/CR10971A/es unknown
-
2010
- 2010-05-03 HK HK10104329.2A patent/HK1138853A1/xx not_active IP Right Cessation
-
2012
- 2012-10-15 HR HRP20120828AT patent/HRP20120828T1/hr unknown
- 2012-11-09 CY CY20121101065T patent/CY1113760T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120828T1 (hr) | Cjepivo | |
| EA200870176A1 (ru) | НОВЫЙ ПОВЕРХНОСТНЫЙ БЕЛОК HAEMOPHILUS INFLUENZAE (БЕЛОК E; pE) | |
| RU2015148746A (ru) | Новый способ клонирования, экспрессии и очистки для получения ранибизумаба | |
| FI3227342T4 (fi) | Proteiininen heterodimeeri ja sen käyttö | |
| PH12020551907A1 (en) | Antagonizing cd73 antibody | |
| WO2006113277A3 (en) | Multivalent soluble tyrokinase receptor that bind angiogenic factor | |
| ATE470673T1 (de) | Impfstoffe mit lawsoniaintrazellularis- untereinheit | |
| WO2008114149A3 (en) | Respiratory syncytial virus (rsv) chimeric polypeptide comprising the g protein central region domain located in between the f2 and f1 fusion protein domains | |
| NZ596735A (en) | Recombinant production of peptides | |
| PL426093A1 (pl) | Fuzyjna polimeraza kwasu jednołańcuchowego DNA Bst, cząsteczka kwasu nukleinowego kodująca fuzyjną polimerazę DNA NeqSSB-Bst, sposób jej otrzymywania oraz zastosowanie | |
| JP2010532656A5 (hr) | ||
| WO2016130628A8 (en) | Griffithsin mutants | |
| EP4269562A3 (en) | Antigen binding molecules and methods of use thereof | |
| MX2020001058A (es) | Marcadores de fusión para expresión de proteínas recombinantes. | |
| WO2019227106A9 (en) | Tumor-specific neoantigens and methods of using the same | |
| SV2017005545A (es) | Fusiones de variante iii del receptor de factor de crecimiento epidermico-mesotelina y metodos para usar los mismos | |
| WO2007045019A3 (en) | Polyoleosins | |
| WO2002070647A8 (en) | Denaturat stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same and their uses | |
| ATE450545T1 (de) | Impfstoff mit lawsonia intracellularis- untereinheit | |
| WO2015175732A3 (en) | Recurrent fusion genes in human cancers | |
| DE602004032143D1 (de) | Hybrid-toxine mit shiga-artigen toxin-untereinheiten, verbunden mit escherichia coli wärmeinstabilen enterotoxin-untereinheiten und vakzine daraus | |
| MX2010000232A (es) | Metodos mejorados para la formacion de enlaces disulfuro. | |
| WO2008109757A3 (en) | Methods and compositions involving polymeric immunoglobulin fusion proteins | |
| WO2004058181A3 (en) | Vmp-like sequences of pathogenic borrelia species and strains | |
| WO2015077506A3 (en) | Identification of a novel b cell cytokine |